Bactericidal activity and resistance development profiling of dalbavancin

Area of Science:

• Pharmacology and Microbiology
• Antimicrobial Agents

Background:

• Dalbavancin is a novel lipoglycopeptide antibiotic.
• It is under development for treating skin and skin structure infections (SSSIs).
• Dalbavancin possesses a long half-life (5-7 days), suggesting potential for weekly dosing.

Purpose of the Study:

• To evaluate the in vitro bactericidal activity of dalbavancin.
• To assess activity against relevant pathogens using clinically relevant concentrations.
• To investigate the potential for resistance development.

Main Methods:

• Minimal bactericidal concentrations (MBCs) were determined for Staphylococcus and Streptococcus isolates.
• Time-kill studies were performed using various strains, including methicillin-susceptible and resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-intermediate Staphylococcus aureus (VISA).
• Resistance development was assessed via direct selection and serial passage methods.

Main Results:

• Dalbavancin exhibited low MBCs (≤0.5 µg/mL) against staphylococcal isolates and potent activity (MICs=0.008 µg/mL) against Streptococcus pyogenes.
• Time-kill studies showed a ≥3-log10 decrease in viable counts for all tested strains exposed to 1 µg/mL dalbavancin for 24 hours.
• Resistance development studies indicated a low frequency of resistance (<10⁻¹⁰) and no stable mutants with decreased susceptibility.

Conclusions:

• Dalbavancin displays significant in vitro bactericidal activity against common SSSI pathogens.
• The drug's efficacy and low resistance potential support its use in managing SSSIs.
• Dalbavancin's pharmacokinetic profile supports a convenient weekly dosing regimen.